[go: up one dir, main page]

WO2024243488A3 - Formulations containing tryptamine derivatives and uses thereof - Google Patents

Formulations containing tryptamine derivatives and uses thereof Download PDF

Info

Publication number
WO2024243488A3
WO2024243488A3 PCT/US2024/030937 US2024030937W WO2024243488A3 WO 2024243488 A3 WO2024243488 A3 WO 2024243488A3 US 2024030937 W US2024030937 W US 2024030937W WO 2024243488 A3 WO2024243488 A3 WO 2024243488A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
disorders
formulations containing
tryptamine derivatives
containing tryptamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/030937
Other languages
French (fr)
Other versions
WO2024243488A2 (en
Inventor
Jacqueline L. Salm
Christopher G. Witowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psilera Inc
Original Assignee
Psilera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psilera Inc filed Critical Psilera Inc
Priority to AU2024275806A priority Critical patent/AU2024275806A1/en
Publication of WO2024243488A2 publication Critical patent/WO2024243488A2/en
Publication of WO2024243488A3 publication Critical patent/WO2024243488A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pharmaceutical compositions that comprise therapeutically effective amounts of a psychedelics may be used to treat, to manage or to prevent neurological, psychiatric and other diseases and disorders. Through delivery of these compounds, one may safely and effectively allow subjects to address the undesirable symptoms of these diseases and disorders and/or the diseases and disorders themselves.
PCT/US2024/030937 2023-05-24 2024-05-24 Formulations containing tryptamine derivatives and uses thereof Pending WO2024243488A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024275806A AU2024275806A1 (en) 2023-05-24 2024-05-24 Formulations containing tryptamine derivatives and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363504034P 2023-05-24 2023-05-24
US63/504,034 2023-05-24

Publications (2)

Publication Number Publication Date
WO2024243488A2 WO2024243488A2 (en) 2024-11-28
WO2024243488A3 true WO2024243488A3 (en) 2025-03-27

Family

ID=93590404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/030937 Pending WO2024243488A2 (en) 2023-05-24 2024-05-24 Formulations containing tryptamine derivatives and uses thereof

Country Status (2)

Country Link
AU (1) AU2024275806A1 (en)
WO (1) WO2024243488A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc New compositions of pharmaceutical substances and preparations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346347A1 (en) * 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
WO2022243285A1 (en) * 2021-05-17 2022-11-24 Cybin Irl Limited Formulations of psilocybin
WO2023076150A1 (en) * 2021-10-29 2023-05-04 Psilera Inc. Modified indole compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210346347A1 (en) * 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
WO2022243285A1 (en) * 2021-05-17 2022-11-24 Cybin Irl Limited Formulations of psilocybin
WO2023076150A1 (en) * 2021-10-29 2023-05-04 Psilera Inc. Modified indole compounds

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 12 August 2020 (2020-08-12), "1-[3-[2-(dimethylamino)ethyl]-1H-indol-4-yl]-N- methylmethanesulfonamide", XP093295959, Database accession no. CID 149771082 *
DATABASE Pubchem 20 December 2022 (2022-12-20), "[3-[2-[di(propan-2-yl)amino]ethyl]-1H-indol-4-yl] dihydrogen phosphate", XP093295970, Database accession no. CID 166138444 *
DATABASE Pubchem 30 November 2021 (2021-11-30), "[2-bromo-3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] acetate", XP093295943, Database accession no. CID 157042555 *
DATABASE Pubchem 6 February 2022 (2022-02-06), "[3-[2-(dimethylamino)ethyl]-2-fluoro-1H-indol-4-yl] acetate", XP093295944, Database accession no. CID 162478146 *
DATABASE Pubchem 6 February 2022 (2022-02-06), "3-[2-(dimethylamino) ethyl]-2-fluoro-1H-indol-4-ol", XP093295949, Database accession no. CID 162478135 *
DATABASE PubChem 6 June 2008 (2008-06-06), "4-Acetoxy-N,N-diisopropyltryptamine", XP093295963, Database accession no. CID 24801868 *
DATABASE Pubchem 6 June 2008 (2008-06-06), "N-Isopropyl-N-(2-(4-methoxy-1H-indol-3-yl)ethyl)propan-2- amine", XP093295966, Database accession no. CID 24802108 *

Also Published As

Publication number Publication date
WO2024243488A2 (en) 2024-11-28
AU2024275806A1 (en) 2025-11-20

Similar Documents

Publication Publication Date Title
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EA200100872A1 (en) COMPOSITION VALDEKOKSIBA
AU2020259997B2 (en) Compounds and methods for the treatment of ocular disorders
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2024243488A3 (en) Formulations containing tryptamine derivatives and uses thereof
MA55199B1 (en) (N-)ACETYL-L-LEUCINE FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY
CA3200722A1 (en) Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
WO2022173888A8 (en) Pharmaceutically acceptable salts of psilocin and uses thereof
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
JP2016528171A5 (en)
MX2021003508A (en) 5-azaindazole derivatives as adenosine receptor antagonists.
CA2534303A1 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
MA53372B1 (en) Pyridopyrimidinenes as histamine h4 receptor inhibitors
WO2023158955A3 (en) 3α-OH-5β-PREGNAN-20-ONE COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS
WO2023009817A3 (en) Phosphate prodrugs of cannabinoids
CA2173839A1 (en) Transferrin compositions to alleviate the side effects of cytotoxic drugs
MX2023005071A (en) N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof.
MA29329B1 (en) AMIDE DERIVATIVES AS ION CHANNEL LIGANDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
WO2024115797A3 (en) Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases
JPS554397A (en) Novel n11benzoylln22phenyll1*33diaminopropane 22ol*its manufacture and medicine containing it for therapy of acute and chronic gastritis
AU2024266044A1 (en) Fused bicyclic heterocyclyl compounds as ccr4 modulators
WO2024211252A3 (en) Modulators of trpml, their compositions and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024275806

Country of ref document: AU